Thermo Fisher Scientific Inc. (TMO) Earnings Call Transcripts

Thermo Fisher Scientific Inc.'s Latest Earnings Call - September 15, 2026

In the Q2 2026 earnings call for Thermo Fisher Scientific Inc., management reported a strong quarter with organic growth of 5% and a 13% increase in EPS, leading to an upward revision of the full-year organic growth outlook to approximately 4%. The company highlighted robust demand from the pharmaceutical and biotech sectors, which constitute 60% of its revenue, and noted that improvements in funding and customer relationships are driving this momentum. Overall, the company is well-positioned for continued growth, with a positive outlook for the second half of the year and beyond.

Reported metrics

Guidance from management

Thermo Fisher expects organic growth of approximately 4% for the full year 2026, with a balanced outlook between Q3 and Q4. Management expressed confidence in achieving this guidance based on strong order momentum and improving end markets.

What management said

Yes. I think the anxiety is literally only a U.S. dynamic, right, in terms of it. In terms of the way I would think about -- we have very strong adoption of our technologies, particularly in our mass spectrometry category. And what you're seeing is Europe was even stronger because they don't have -- they have less of the sort of policy things that they're working through. The U.S. was positive. China continues to be ...

Yes. I mean when I think about the long-term growth for this business, I always think about it as a high single, low double-digit growth in aggregate. And we've been able to -- coming through 2019, sort of in that period, we were able to grow at that rate for a long period of time. We had supersized growth in the beginning of the pandemic. The whole industry had the hangover effect, which we all want to forget, and n...

What analysts pressed on

Analysts raised concerns about the lag between biotech funding and revenue generation, questioning how long it will take for increased funding to translate into actual sales. Additionally, there were inquiries about the potential impact of economic uncertainties on growth projections.

Main topics on the call

• Strong Organic Growth — Thermo Fisher achieved 5% organic growth in Q2, marking the strongest growth since 2021. CEO Marc Casper stated, "It's setting up to be really an outstanding year," reflecting confidence in the company's operational perf...
• Pharma and Biotech Demand — The pharma and biotech segments grew mid-single digits, with Casper noting that "pharmaceutical customers are quite positive" and that funding improvements are translating into spending. This sector represents 60% of The...
• Reshoring Opportunities — Management discussed the trend of reshoring production to the U.S., which is expected to create a multi-year investment cycle. Casper mentioned, "We've secured a number of large contracts for our capability to produce in...
• Clinical Research Growth — The clinical research segment is performing well, with strong authorizations growth. Casper highlighted that the company is leveraging AI to enhance efficiency in drug development, stating, "We've demonstrated the benefi...

Read the full Thermo Fisher Scientific Inc. transcript (September 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 81 Thermo Fisher Scientific Inc. earnings call transcripts on record, spanning January 14, 2020 to September 15, 2026. Based on this history, Thermo Fisher Scientific Inc. reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

TMO

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

81

First call

January 14, 2020

Most recent

September 15, 2026

Reporting cadence

quarterly